Hepatitis C virus (HCV) is a positive-strand RNA virus grouped in the genus Hepacivirus within the family Flaviviridae. HCV is classified into at least 6 genotypes (gt), and its error-prone polymerase leads to more than 50 subtypes. The long open reading frame, which encodes the HCV polyprotein, is processed by host and viral proteases and gives rise to three structural proteins (the capsid protein core and envelope glycoproteins E1 and E2) and seven nonstructural (NS) proteins (p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B). NS2 and p7 are essential for virus assembly but not RNA replication, whereas NS3 to NS5B are involved in a membrane-associated RNA replicase complex (RC). The NS3 protein is composed of a serine protease and an RNA helicase/nucleoside triphosphatase (NTPase), NS4A serves as a cofactor for NS3 serine protease, NS5B is the RNA-dependent RNA polymerase, and NS5A is considered to play key roles in multiple steps of the HCV life cycle. NS5A inhibitors exhibit a rapid inhibition of virus infectivity shortly after administration to HCV-infected cells. The HCV protein NS5A prevents the apoptosis-enabling loss of intracellular potassium by inhibiting Kv2.1 function and thus blocking hepatocyte cell death. The HCV RNA-dependent RNA polymerase (RdRp) has long been a prime target for antiviral development because of its critical role in viral replication and the absence of a mammalian homologous enzyme. The combination of lucidone and alpha interferon, the protease inhibitor Telaprevir, the NS5A inhibitor BMS-790052, or the NS5B polymerase inhibitor PSI-7977, synergistically suppresses HCV RNA replication.
# HCV Inhibitors & Modulators

## 4-Phenoxybenzylamine

**Cat. No.:** HY-18563

**Bioactivity:** 4-Phenoxybenzylamine inhibits the function of the NS3 protein by stabilizing an inactive conformation with an IC\textsubscript{50} of about 500 μM against FL NS3/4a.

**Purity:** 96.69%

**Clinical Data:** No Development Reported

**Size:** 10mM x 1mL in DMSO, 100 mg

## ABT-072

**Cat. No.:** HY-101634

**Bioactivity:** ABT-072 is a nonnucleoside NS5B polymerase inhibitor and a candidate drug evaluated for treatment of hepatitis C virus.

**Purity:** 99.0%

**Clinical Data:** Phase 2

**Size:** 1 mg, 5 mg, 10 mg, 20 mg

## ACH-806

*(GS9132)*

**Cat. No.:** HY-19512

**Bioactivity:** ACH-806 is an NS5A antagonist which can inhibit Hepatitis C Virus (HCV) replication with an EC\textsubscript{50} of 14 nM.

**Purity:** >98%

**Clinical Data:** No Development Reported

**Size:** 1 mg, 5 mg, 10 mg

## Alisporivir

*(DEB-025; Debio-025; UNIL-025)*

**Cat. No.:** HY-12559

**Bioactivity:** Alisporivir (DEB-025; Debio-025) is a cyclophilin inhibitor molecule with potent anti-hepatitis C virus (HCV) activity.

**Purity:** 98.67%

**Clinical Data:** No Development Reported

**Size:** 1 mg, 5 mg

## Anguizole

**Cat. No.:** HY-13321

**Bioactivity:** Anguizole is a small molecule inhibitor of HCV replication and alters NS4B’s subcellular distribution.

**Purity:** 99.33%

**Clinical Data:** No Development Reported

**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg

## Artemisinin

*(Qinghaosu; NSC 369397)*

**Cat. No.:** HY-B0094

**Bioactivity:** Artemisinin is an anti-malarial drug isolated from the aerial parts of Artemisia annua L. plants.

**Purity:** 98.0%

**Clinical Data:** Launched

**Size:** 10mM x 1mL in DMSO, 200 mg, 500 mg

## Asunaprevir

*(BMS-650032)*

**Cat. No.:** HY-14434

**Bioactivity:** Asunaprevir is a potent hepatitis C virus (HCV) NS3 protease inhibitor, with IC\textsubscript{50} of 0.2 nM-3.5 nM.

**Purity:** 99.27%

**Clinical Data:** Phase 4

**Size:** 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg

## Balapiravir

*(Ro 4588161; R1626)*

**Cat. No.:** HY-10443

**Bioactivity:** Balapiravir (R1626, Ro 4588161) is the prodrug of a nucleoside analogue inhibitor of the hepatitis C virus (HCV) RNA-dependent RNA polymerase (R1479, RG1479).

**Purity:** 98.11%

**Clinical Data:** Phase 2

**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg

## Beclabuvir

*(BMS-791325)*

**Cat. No.:** HY-12429

**Bioactivity:** Beclabuvir is an allosteric inhibitor that binds to thumb site 1 of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase, and inhibits recombinant NS5B proteins from HCV genotypes 1, 3, 4, and 5 with IC\textsubscript{50} of < 28 nM.

**Purity:** 99.81%

**Clinical Data:** Phase 3

**Size:** 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

## Boceprevir

*(EBP 520; SCH 503034)*

**Cat. No.:** HY-10237

**Bioactivity:** Boceprevir is a novel, potent, highly selective, orally bioavailable HCV NS3 protease inhibitor with K\textsubscript{i} of 14 nM in both enzyme assay and EC\textsubscript{50} of 350 nM in cell-based replicon assay.

**Purity:** 99.12%

**Clinical Data:** Launched

**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg
### Bioactivity:
Celgosivir (MBI 3253; MDL 28574; MX3253) is a novel α-glucosidase I inhibitor, an enzyme that plays a critical role in viral maturation by initiating the processing of the N-linked oligosaccharides of viral envelope protease.[1]

### Clemizole hydrochloride
Cat. No.: HY-30234A

### Bioactivity:
Celgosivir hydrochloride (MBI 3253 (hydrochloride); MDL 28574 (hydrochloride); MX3253 (hydrochloride)) is a novel α-glucosidase I inhibitor; inhibits bovine viral diarrhoea virus (BVDV) with an IC50 of 1.27 μM in vitro assay.

### Clemizole
Cat. No.: HY-30234

### Bioactivity:
Celgosivir hydrochloride is an α-glucosidase I inhibitor, an enzyme that plays a critical role in viral maturation by initiating the processing of the N-linked oligosaccharides of viral envelope protease.

### Clemizole hydrochloride
Cat. No.: HY-30234A

### Bioactivity:
Clemizole hydrochloride is an α-glucosidase I inhibitor; inhibits bovine viral diarrhoea virus (BVDV) with an IC50 of 1.27 μM in vitro assay.

### Cyclophilin inhibitor 1
Cat. No.: HY-112712

### Bioactivity:
Cyclophilin inhibitor 1 is a potent and orally bioavailable cyclophilin A inhibitor, with a K_i of 5 nM, shows effective anti- HCV activity, with an EC50 of 98 nM for HCV 2a [1].

### Daclatasvir dihydrochloride
Cat. No.: HY-10465

### Bioactivity:
Daclatasvir dihydrochloride (BMS-790052 dihydrochloride) is a highly selective inhibitor of HCV NS5A with EC50 of 9-50 pM, for a broad range of HCV replicon genotypes and the JFH-1 genotype 2a infectious virus in cell culture. IC50 Value: 9-50 pM Target: HCV NS5A Daclatasvir has broad genotype coverage...

### Daclatasvir
Cat. No.: HY-10466

### Bioactivity:
Daclatasvir is a potent HCV NS5A protein inhibitor, with mean EC50 values of 50 and 9 pM against genotype 1a and 1b replicons, respectively.

### Danoprevir
Cat. No.: HY-10238

### Bioactivity:
Danoprevir is a NS3/4A protease inhibitor for hepatitis C virus (HCV) with IC50 of 0.2-3.5 nM. The inhibition effect on HCV genotypes 1A/1B/4/5/6 is approximately 10-fold higher than 2B/3A.

### Dasabuvir
Cat. No.: HY-13998

### Bioactivity:
Dasabuvir (ABT-333) is a nonnucleoside inhibitor of the RNA-dependent RNA polymerase encoded by the HCV NS5B gene, inhibits recombinant NS5B polymerases derived from HCV genotype 1a and 1b clinical isolates, with IC50 between 2.2 and 10.7 nM. 98.05% Purity: Cat. No.: HY-15789

### Bioactivity:
Elbasvir (MK-8742) is a hepatitis C virus nonstructural protein 5A (HCV NS5A) inhibitor with EC50s of 4, 3 and 3 nM against genotype 1a, 1b, and 2a, respectively.

### Elbasvir
Cat. No.: HY-15789
### Furaprofen (R803)  
**Cat. No.:** HY-U00213  
**Bioactivity:** Furaprofen (R803) is an effective **HCV replication** inhibitor. Furaprofen (R803) is substantially more potent against genotype **1a** and **1b** replicons (EC50 ~30 nM) than against the genotype 2a replicon (EC50 ~1,000 nM).  
**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 1 mg, 5 mg, 10 mg, 20 mg

### Glecaprevir (ABT-493)  
**Cat. No.:** HY-17634  
**Bioactivity:** Glecaprevir is a novel **HCV NS3/4A protease** inhibitor, with IC50 values ranging from 3.5 to 11.3 nM.  
**Purity:** 99.65%  
**Clinical Data:** Launched  
**Size:** 10 mM x 1 mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg

### Grazoprevir (MK-5172)  
**Cat. No.:** HY-15298  
**Bioactivity:** Grazoprevir (MK-5172) is a selective inhibitor of **Hepatitis C virus NS3/4a** protease with broad activity across genotypes and resistant variants, with Kd values for genotypes 1a (0.08 nM), 1b (0.15 nM), 2a (0.90 nM), respectively.  
**Purity:** 99.21%  
**Clinical Data:** Launched  
**Size:** 10 mM x 1 mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

### Grazoprevir hydrate (MK-5172 hydrate)  
**Cat. No.:** HY-15298B  
**Bioactivity:** Grazoprevir hydrate (MK-5172 hydrate) is a selective inhibitor of **Hepatitis C virus NS3/4a** protease with broad activity across genotypes and resistant variants, with Kd values for genotypes 1a (0.08 nM), 1b (0.15 nM), 2a (0.90 nM), respectively.  
**Purity:** >98%  
**Clinical Data:** Launched  
**Size:** 10 mM x 1 mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

### Grazoprevir potassium salt (MK-5172 potassium salt)  
**Cat. No.:** HY-15298A  
**Bioactivity:** Grazoprevir potassium salt (MK-5172 potassium salt) is a selective inhibitor of **Hepatitis C virus NS3/4a** protease with broad activity across genotypes and resistant variants, with Kd values for genotypes 1a (0.08 nM), 1b (0.15 nM), 2a (0.90 nM), respectively.  
**Purity:** >98%  
**Clinical Data:** Launched  
**Size:** 10 mM x 1 mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

### Grazoprevir sodium salt (MK-5172 sodium salt)  
**Cat. No.:** HY-15298C  
**Bioactivity:** Grazoprevir sodium salt (MK-5172 sodium salt) is a selective inhibitor of **Hepatitis C virus NS3/4a** protease with broad activity across genotypes and resistant variants, with Kd values for genotypes 1a (0.08 nM), 1b (0.15 nM), 2a (0.90 nM), respectively.  
**Purity:** >98%  
**Clinical Data:** Launched  
**Size:** 5 mg, 10 mg, 50 mg, 100 mg

### HCV-IN-3  
**Cat. No.:** HY-18564  
**Bioactivity:** HCV-IN-3 is a **hepatitis C virus (HCV) NS3/4a** protein inhibitor, with an IC50 of 20 μM, a Kd of 29 μM.  
**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 250 mg, 500 mg

### Inarigivir soproxil (SB8200)  
**Cat. No.:** HY-109035  
**Bioactivity:** Inarigivir soproxil is an agonist of innate immunity and shows potent antiviral activity against resistant hepatitis C virus (HCV) variants, with EC50 of 2.2 and 1 μM for HCV 1a/1b in cells of genotype 1 HCV replicon systems.  
**Purity:** 98.16%  
**Clinical Data:** No Development Reported  
**Size:** 10 mM x 1 mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

### JTK-853  
**Cat. No.:** HY-19921  
**Bioactivity:** JTK-853 is a novel, non-nucleoside **Hepatitis C Virus (HCV) polymerase** inhibitor which shows effective antiviral activity in HCV replicon cells with EC50 of 0.38 and 0.035 μM in genotype 1a H77 and 1b Con1 strains, respectively.  
**Purity:** >98%  
**Clinical Data:** No Development Reported  
**Size:** 1 mg, 5 mg, 10 mg

### KIN1408  
**Cat. No.:** HY-19961  
**Bioactivity:** KIN1408 is an antiviral small molecule compound, as agonists of the RLR pathway. Target: KIN1408 activate IFI3 through MAVS, thereby inhibiting infection by viruses of the families Flaviviridae (West Nile virus, dengue virus and hepatitis C virus), Filoviridae (Ebola virus), Orthomyxoviridae (influenza...  
**Purity:** 99.55%  
**Clinical Data:** No Development Reported  
**Size:** 10 mM x 1 mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg

---

**Bioactivity:** Furaprofen (R803) is an effective HCV replication inhibitor. Furaprofen (R803) is substantially more potent against genotype 1a and 1b replicons (EC50 ~30 nM) than against the genotype 2a replicon (EC50 ~1,000 nM).

**Purity:** >98%

**Clinical Data:** No Development Reported

**Size:** 1 mg, 5 mg, 10 mg, 20 mg

**Bioactivity:** Glecaprevir is a novel HCV NS3/4A protease inhibitor, with IC50 values ranging from 3.5 to 11.3 nM.

**Purity:** 99.65%

**Clinical Data:** Launched

**Size:** 10 mM x 1 mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg

**Bioactivity:** Grazoprevir (MK-5172) is a selective inhibitor of Hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants, with Kd values for genotypes 1a (0.08 nM), 1b (0.15 nM), 2a (0.90 nM), respectively.

**Purity:** 99.21%

**Clinical Data:** Launched

**Size:** 10 mM x 1 mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

**Bioactivity:** Grazoprevir hydrate (MK-5172 hydrate) is a selective inhibitor of Hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants, with Kd values for genotypes 1a (0.08 nM), 1b (0.15 nM), 2a (0.90 nM), respectively.

**Purity:** >98%

**Clinical Data:** Launched

**Size:** 10 mM x 1 mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

**Bioactivity:** Grazoprevir potassium salt (MK-5172 potassium salt) is a selective inhibitor of Hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants, with Kd values for genotypes 1a (0.08 nM), 1b (0.15 nM), 2a (0.90 nM), respectively.

**Purity:** >98%

**Clinical Data:** Launched

**Size:** 10 mM x 1 mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

**Bioactivity:** Grazoprevir sodium salt (MK-5172 sodium salt) is a selective inhibitor of Hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants, with Kd values for genotypes 1a (0.08 nM), 1b (0.15 nM), 2a (0.90 nM), respectively.

**Purity:** >98%

**Clinical Data:** Launched

**Size:** 5 mg, 10 mg, 50 mg, 100 mg

**Bioactivity:** HCV-IN-3 is a hepatitis C virus (HCV) NS3/4a protein inhibitor, with an IC50 of 20 μM, a Kd of 29 μM.

**Purity:** >98%

**Clinical Data:** No Development Reported

**Size:** 250 mg, 500 mg

**Bioactivity:** Inarigivir soproxil is an agonist of innate immunity and shows potent antiviral activity against resistant hepatitis C virus (HCV) variants, with EC50 of 2.2 and 1 μM for HCV 1a/1b in cells of genotype 1 HCV replicon systems.

**Purity:** 98.16%

**Clinical Data:** No Development Reported

**Size:** 10 mM x 1 mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

**Bioactivity:** JTK-853 is a novel, non-nucleoside Hepatitis C Virus (HCV) polymerase inhibitor which shows effective antiviral activity in HCV replicon cells with EC50 of 0.38 and 0.035 μM in genotype 1a H77 and 1b Con1 strains, respectively.

**Purity:** >98%

**Clinical Data:** No Development Reported

**Size:** 1 mg, 5 mg, 10 mg

**Bioactivity:** KIN1408 is an antiviral small molecule compound, as agonists of the RLR pathway. Target: KIN1408 activate IFI3 through MAVS, thereby inhibiting infection by viruses of the families Flaviviridae (West Nile virus, dengue virus and hepatitis C virus), Filoviridae (Ebola virus), Orthomyxoviridae (influenza...  

**Purity:** 99.55%

**Clinical Data:** No Development Reported

**Size:** 10 mM x 1 mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg
**Bioactivity:** Ledipasvir is an inhibitor of the hepatitis C virus NS5A, with EC$_{50}$ values of 34 pM against GT1a and 4 pM against GT1b replicon.

**Purity:** 99.96%
**Clinical Data:** Launched
**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

**Bioactivity:** Ledipasvir acetone is the active pharmaceutical ingredient of Ledipasvir. Ledipasvir is an inhibitor of the hepatitis C virus NS5A, with EC$_{50}$ values of 34 pM against GT1a and 4 pM against GT1b replicon.

**Purity:** 99.95%
**Clinical Data:** Phase 2
**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

**Bioactivity:** Mecarbinate is an anti-hepatitis C virus (HCV) agent.

**Purity:** 98.34%
** Clinical Data:** No Development Reported
**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg

**Bioactivity:** Merimepodib is a noncompetitive and oral inhibitor of inosine monophosphate dehydrogenase (IMPDH) with broad spectrum antiviral activities.

**Purity:** 98.22%
**Clinical Data:** Phase 4
**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

**Bioactivity:** NIM811 ((Melle-4)cyclosporin; SDZ NIM811) is a potent and bioavailable mitochondrial permeability transition and cyclophilin dual inhibitor, which exhibits potent in vitro activity against hepatitis C virus (HCV) [1] [2].

**Purity:** 99.55%
**Clinical Data:** Phase 2
**Size:** 10mM x 1mL in DMSO, 1 mg, 5 mg
NM107  
(2’-C-Methylcytidine; NM-107)  
Cat. No.: HY-10468

**Bioactivity:**  NM107 is a inhibitors of HCV RNA replication with IC50 of 7.0 μM in vitro.

**Purity:**  99.52%
**Clinical Data:**  No Development Reported
**Size:**  10mM x 1mL in Water, 5 mg, 10 mg, 50 mg, 100 mg

---

Nucleoside-Analog-1

Cat. No.: HY-77651

**Bioactivity:**  Nucleoside-Analog-1 is a 4’-Azidocytidine analogue against Hepatitis C virus replication.

**Purity:**  95.0%
**Clinical Data:**  No Development Reported
**Size:**  10mM x 1mL in Water, 5 mg, 10 mg, 50 mg, 100 mg

---

Nucleoside-Analog-2

Cat. No.: HY-77652

**Bioactivity:**  Nucleoside-Analog-2 is a 4’-Azidocytidine analogue against Hepatitis C virus (HCV) replication.

**Purity:**  95.0%
**Clinical Data:**  No Development Reported
**Size:**  10mM x 1mL in Water, 5 mg, 10 mg, 50 mg, 100 mg

---

Paritaprevir  
(ABT-450; Veruprevir)  
Cat. No.: HY-12594

**Bioactivity:**  Paritaprevir (ABT-450) is a potent non-structural protein 3/4A (NS3/4A) protease inhibitor with EC50 of 1 and 0.21 nM against HCV 1a and 1b, respectively.

**Purity:**  99.85%
**Clinical Data:**  Phase 4
**Size:**  10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

---

Peretinoin  
(NIK333)  
Cat. No.: HY-100008

**Bioactivity:**  Peretinoin is an oral acyclic retinoid, inhibits HCV RNA amplification and virus release by altering lipid metabolism. Target: HCV in vitro; Peretinoin is an acyclic retinoid, improves the hepatic gene signature of chronic hepatitis C following curative therapy of hepatocellular carcinoma....

**Purity:**  98.38%
**Clinical Data:**  Phase 3
**Size:**  10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

---

PSI-352938  
(PSI-938)  
Cat. No.: HY-15231

**Bioactivity:**  PSI-352938 (PSI-938) is a hepatitis C virus (HCV) nucleotide inhibitor.

**Purity:**  >98%
**Clinical Data:**  Phase 1
**Size:**  1 mg, 5 mg, 10 mg, 20 mg

---

PSI-6130  
(R 1656)  
Cat. No.: HY-10165

**Bioactivity:**  PSI-6130 is a potent and selective inhibitor of HCV NS5B polymerase, and inhibits HCV replication with a mean IC50 of 0.6 μM.

**Purity:**  99.39%
**Clinical Data:**  No Development Reported
**Size:**  10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg

---

PSI-6206  
(RO 2433; GS-331007)  
Cat. No.: HY-15236

**Bioactivity:**  PSI-6206 is the deaminated derivative of PSI-6130, which is a potent and selective inhibitor of HCV NS5B polymerase. PSI-6206 low potently inhibits HCV replicon with EC90 of >100 μM.

**Purity:**  99.89%
**Clinical Data:**  No Development Reported
**Size:**  10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg

---

PSI-6206 13CD3  
(RO-2433 13CD3; GS-331007 13CD3; Sofosbuvir metabolite GS-331007 13CD3)  
Cat. No.: HY-15236S

**Bioactivity:**  PSI-6206 13CD3 is the deuterium labeled PSI-6206. PSI-6206 is the deaminated derivative of PSI-6130, which is a potent and selective inhibitor of HCV NS5B polymerase. PSI-6206 low potently inhibits HCV replicon with EC90 of >100 μM.

**Purity:**  99.0%
**Clinical Data:**  No Development Reported
**Size:**  10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg
**Bioactivity:** PSI-7409 is the active 5'-triphosphate metabolite of Sofosbuvir (PSI-7977). Sofosbuvir (PSI-7977) is a selective and highly active nucleotide analog inhibitor of HCV.

**Purity:** 96.49%

**Clinical Data:** No Development Reported

**Size:** 1 mg, 5 mg

---

**Bioactivity:** PSI-7409 tetrasodium is an active 5'-triphosphate metabolite of sofosbuvir (PSI-7977), inhibiting HCV NS5B polymerases, with $IC_{50}$ of 1.6, 2.8, 0.7 and 2.6 μM for GT 1b, Con1, GT 2a, JJH1, GT 3a, and GT 4a NS5B polymerases, respectively.

**Purity:** 96.49%

**Clinical Data:** No Development Reported

**Size:** 10mM x 1mL in Water, 1 mg, 5 mg, 10 mg, 25 mg

---

**Bioactivity:** PSI-7976 tetrasodium is an active 5'-triphosphate metabolite of sofosbuvir (PSI-7977), inhibiting HCV NS5B polymerases with $IC_{50}$ of 1.6, 2.8, 0.7 and 2.6 μM for GT 1b_Con1, GT 2a_JFH1, GT 3a, and GT 4a NS5B polymerases, respectively.

**Purity:** 99.24%

**Clinical Data:** No Development Reported

**Size:** 10mM x 1mL in DMSO, 1 mg, 5 mg

---

**Bioactivity:** R-1479 (4'-Azidocytidine) is a specific inhibitor of HCV replication in the HCV subgenomic replicon system with $IC_{50}$ of 1.28 μM.

**Purity:** 99.44%

**Clinical Data:** No Development Reported

**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

---

**Bioactivity:** Ribavirin (ICN-1229) is an antiviral agent against a broad spectrum of viruses including HCV, HIV, and RSV.

**Purity:** 98.0%

**Clinical Data:** Launched

**Size:** 10mM x 1mL in Water, 100 mg, 200 mg, 500 mg

---

**Bioactivity:** RIG-1 modulator 1 is an anti-viral compound which can be useful for the treatment of viral infections including influenza virus, HBV, HCV and HIV extracted from patent WO 2015172099 A1.

**Purity:** 98.81%

**Clinical Data:** No Development Reported

**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

---

**Bioactivity:** RO-9187 is a potent inhibitor of HCV virus replication with an $IC_{50}$ of 171 nM.

**Purity:** 98.0%

**Clinical Data:** No Development Reported

**Size:** 10mM x 1mL in Water, 5 mg, 10 mg, 50 mg

---

**Bioactivity:** Simeprevir is a potent HCV NS3/4A protease inhibitor which suppresses HCV replication with $EC_{50}$ of 8 nM.

**Purity:** 99.34%

**Clinical Data:** Launched

**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg

---

**Bioactivity:** Sofosbuvir (PSI-7977; GS 7977) is an HCV RNA replication inhibitor with an $EC_{50}$ of 92 nM.

**Purity:** 99.99%

**Clinical Data:** Launched

**Size:** 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 500 mg, 1 g

---

**Bioactivity:** Sofosbuvir 13CD3 is the deuterium labeled Sofosbuvir. Sofosbuvir (PSI-7977) is an active inhibitor of HCV RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (HCV) activity.

**Purity:** >98%

**Clinical Data:** No Development Reported

**Size:** 1 mg, 5 mg

---
Bioactivity:
Sofosbuvir D6 is the deuterium labeled Sofosbuvir. Sofosbuvir (PSI-7977) is an active inhibitor of HCV RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (HCV) activity.

Purity: >98%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg

Bioactivity:
Sofosbuvir impurity A, an diastereoisomer of sofosbuvir, is the impurity of sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of HCV RNA replication, demonstrates potent anti-hepatitis C virus activity.

Purity: >98%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg

Bioactivity:
Sofosbuvir impurity B is the less active impurity of Sofosbuvir. Sofosbuvir is an active inhibitor of HCV RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (HCV) activity.

Purity: >98%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg

Bioactivity:
Sofosbuvir impurity C is the less active impurity of Sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of HCV RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus activity.

Purity: >98%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg

Bioactivity:
Sofosbuvir impurity D is the less active impurity of Sofosbuvir. Sofosbuvir is an active inhibitor of HCV RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (HCV) activity.

Purity: >98%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg

Bioactivity:
Sofosbuvir impurity F, an diastereoisomer of sofosbuvir, is the impurity of sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of HCV RNA replication, demonstrates potent anti-hepatitis C virus activity.

Purity: >98%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg

Bioactivity:
Sofosbuvir impurity H, an diastereoisomer of sofosbuvir, is the impurity of sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of HCV RNA replication, demonstrates potent anti-hepatitis C virus activity.

Purity: >98%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg
Sofosbuvir impurity J

**Cat. No.: HY-I0975**

**Bioactivity:** Sofosbuvir impurity J, an diastereoisomer of sofosbuvir, is the impurity of sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of HCV RNA replication, demonstrates potent anti-hepatitis C virus activity.

**Purity:** >98%

**Clinical Data:** No Development Reported

**Size:**
- 10 mM x 1 mL in DMSO
- 1 mg, 5 mg

Sofosbuvir impurity K

**Cat. No.: HY-I0515**

**Bioactivity:** Sofosbuvir impurity K, an diastereoisomer of sofosbuvir, is the impurity of sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of HCV RNA replication, demonstrates potent anti-hepatitis C virus activity.

**Purity:** 98.97%

**Clinical Data:** No Development Reported

**Size:**
- 10 mM x 1 mL in DMSO
- 1 mg, 5 mg

Sofosbuvir impurity L

**Cat. No.: HY-I1196**

**Bioactivity:** Sofosbuvir impurity L, an diastereoisomer of sofosbuvir, is the impurity of sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of HCV RNA replication, demonstrates potent anti-hepatitis C virus activity.

**Purity:** >98%

**Clinical Data:** No Development Reported

**Size:**
- 10 mM x 1 mL in DMSO
- 1 mg, 5 mg

Sofosbuvir impurity M

**Cat. No.: HY-I0735**

**Bioactivity:** Sofosbuvir impurity M, an diastereoisomer of sofosbuvir, is the impurity of sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of HCV RNA replication, demonstrates potent anti-hepatitis C virus activity.

**Purity:** 99.04%

**Clinical Data:** No Development Reported

**Size:**
- 10 mM x 1 mL in DMSO
- 1 mg, 5 mg

Tegobuvir

**(GS 333126; GS-9190)**

**Cat. No.: HY-10544**

**Bioactivity:** Tegobuvir is a specific, covalent inhibitor of the HCV NS5B polymerase.

**Purity:** 98.52%

**Clinical Data:** Phase 2

**Size:**
- 10 mM x 1 mL in DMSO
- 5 mg, 10 mg, 50 mg

Telaprevir

**(VX-950)**

**Cat. No.: HY-10235**

**Bioactivity:** Telaprevir is a highly selective, reversible, and potent peptidomimetic inhibitor of the HCV NS3-4A protease, the steady-state inhibitory constant (K) of Telaprevir is 7 nM against a genotype 1 (H strain) NS3 protease domain plus a NS4A cofactor peptide. 99.89%

**Clinical Data:** Launched

**Size:**
- 10 mM x 1 mL in DMSO
- 10 mg, 50 mg, 100 mg

Tris(4-aminophenyl)methane

**(Leucopararosaniline)**

**Cat. No.: HY-D0306**

**Bioactivity:** Tris(4-aminophenyl)methane is a triphenylmethane dye. Tris(4-aminophenyl)methane is a weak HCV helicase inhibitor.

**Purity:** >98%

**Clinical Data:** No Development Reported

**Size:**
- 100 mg, 250 mg, 500 mg

Vaniprevir

**(MK-7009)**

**Cat. No.: HY-10243**

**Bioactivity:** Vaniprevir (MK-7009) is a non-covalent competitive inhibitor of the hepatitis C virus (HCV) NS3/4A protease. IC50 Value: Target: HCV NS3/4A Protease; HCV vaniprevir (MK-7009) is a macrocyclic hepatitis C virus NS3/4A protease inhibitor, is active against both the genotype 1 and genotype 2 NS3/4a...

**Purity:** 99.60%

**Clinical Data:** Launched

**Size:**
- 5 mg, 10 mg
### VCH-916

**Bioactivity:** VCH-916 is a novel nonnucleoside HCV NS5B polymerase inhibitor.

<table>
<thead>
<tr>
<th>Purity</th>
<th>99.51%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Data</td>
<td>Phase 1</td>
</tr>
<tr>
<td>Size</td>
<td>10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg</td>
</tr>
</tbody>
</table>

### Velpatasvir

**Bioactivity:** Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons.

<table>
<thead>
<tr>
<th>Purity</th>
<th>99.95%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Data</td>
<td>Launched</td>
</tr>
<tr>
<td>Size</td>
<td>10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg</td>
</tr>
</tbody>
</table>

### VX-222

**Bioactivity:** VX-222 (VCH-222) is a novel, potent and selective inhibitor of HCV polymerase with IC50 of 0.94-1.2 μM, 15.3-fold less effective for mutant M423T, and 108-fold less effective for mutant I482L. IC50 Value: 0.94 μM (HCV NS5B 1a); 1.2 μM (HCV NS5B 1b) Target: HCV VX-222 is a small molecule non-nucleoside...

<table>
<thead>
<tr>
<th>Purity</th>
<th>99.76%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Data</td>
<td>Phase 2</td>
</tr>
<tr>
<td>Size</td>
<td>10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg</td>
</tr>
</tbody>
</table>